AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8573948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment regimens
Number of subjects: 25
Study 8573948 — intervention group
Group type: COMPARATOR
Intervention: Treatment regimens
Number of subjects: 25
Study 2617169 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg o.m. + Amoxicillin 750 mg b.i.d (Group 1)
Number of subjects: 24
Study 2617169 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 750 mg b.i.d (Group 3)
Number of subjects: 24
Study 2617169 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg o.m. (Group 2)
Number of subjects: 24
Study 321487 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (three dose levels)
Number of subjects: 0
Study 321487 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA (three dose levels)
Number of subjects: 0
Study 321487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27105332 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual‐Family Psychoeducational Psychotherapy (PEP)
Number of subjects: 95
Study 27105332 — intervention group
Group type: EXPERIMENTAL
Intervention: omega‐3 supplementation
Number of subjects: 95
Study 27105332 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of omega‐3 and PEP
Number of subjects: 95
Study 27105332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 29625834 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavioral treatment (ICBT) for 12 weeks
Number of subjects: 111
Study 29625834 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided Internet-based cognitive behavioral treatment (ICBT) for 12 weeks
Number of subjects: 111
Study 29625834 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 111
Study 26597925 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus ezetimibe
Number of subjects: 9270
Study 24609919 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 month intervention group (three face to face visits with a lifestyle counsellor plus monthly 15 minute telephone calls)
Number of subjects: 329
Study 24609919 — intervention group
Group type: COMPARATOR
Intervention: Control group (weight loss booklet only)
Number of subjects: 329
Study 24609919 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 month intervention group
Number of subjects: 329
Study 23168106 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification lenses
Number of subjects: 14
Study 23168106 — intervention group
Group type: COMPARATOR
Intervention: Traditional safety lenses
Number of subjects: 14
Study 19369056 — intervention group
Group type: EXPERIMENTAL
Intervention: EGG group (640 mg additional cholesterol)
Number of subjects: 0
Study 19369056 — intervention group
Group type: COMPARATOR
Intervention: CR (10-15% en)
Number of subjects: 0
Study 17671956 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbofilm coated stent (Carbosten)
Number of subjects: 0
Study 17671956 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 0
Study 15574664 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 0
Study 15574664 — intervention group
Group type: COMPARATOR
Intervention: No implementation intentions
Number of subjects: 0
Study 11880821 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g x kg(‐1) x d(‐1) for 7 days)
Number of subjects: 18
Study 11880821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10511768 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (0.7 mg/kg)
Number of subjects: 82
Study 10511768 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (0.7 mg/kg) and Furosemide (1 mg/kg)
Number of subjects: 82
Study 10511768 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (1 mg/kg)
Number of subjects: 82
Study 8835246 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphasalazine (Salazopyrin)
Number of subjects: 23
Study 2046374 — intervention group
Group type: EXPERIMENTAL
Intervention: Special follow-up group (EAP clients with routine contacts from a follow-up counselor)
Number of subjects: 325
Study 2046374 — intervention group
Group type: COMPARATOR
Intervention: Regular care group (EAP clients receiving follow-up only as needed)
Number of subjects: 325
Study 6791883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (17 patients)
Number of subjects: 37
Study 6791883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 patients)
Number of subjects: 37
Study 31548244 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Mdiet
Number of subjects: 28
Study 31548244 — intervention group
Group type: COMPARATOR
Intervention: 6Mdiet
Number of subjects: 28
Study 29103749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus taxanes (TP)
Number of subjects: 806
Study 29103749 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus fluorouracil (PF)
Number of subjects: 806
Study 26932302 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 12.5 mg/metformin 1,000 mg FDC
Number of subjects: 0
Study 26932302 — intervention group
Group type: COMPARATOR
Intervention: Individual tablets of empagliflozin and metformin
Number of subjects: 0
Study 24956099 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrix (CM) plus coronally advanced flap (CAF)
Number of subjects: 32
Study 24956099 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF)
Number of subjects: 32
Study 22228104 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT
Number of subjects: 154
Study 22228104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 22228104 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT (responders)
Number of subjects: 154
Study 22228104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonresponders)
Number of subjects: 154
Study 22228104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (overall)
Number of subjects: 154
Study 18434221 — intervention group
Group type: EXPERIMENTAL
Intervention: Active physical treatment (APT) - 10 weeks of aerobic training and muscle strengthening of back extensors
Number of subjects: 172
Study 18434221 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity plus problem solving training (GAP) - 10 weeks of gradual assumption of patient relevant activities based on operant‐behavioral principles and problem solving training
Number of subjects: 172
Study 18434221 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (CT) - APT combined with GAP
Number of subjects: 172
Study 18434221 — intervention group
Group type: COMPARATOR
Intervention: APT
Number of subjects: 172
Study 18434221 — intervention group
Group type: COMPARATOR
Intervention: GAP
Number of subjects: 172
Study 17126963 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vaccinia Ankara (MVA)
Number of subjects: 0
Study 17126963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16306196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with indomethacin (0.1 mg/kg/24 h for three doses) and L‐NMMA (infusion for 72 hours)
Number of subjects: 50
Study 16306196 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (0.1 mg/kg/24 h for three doses)
Number of subjects: 50
Study 12693434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training (CAT)
Number of subjects: 45
Study 12693434 — intervention group
Group type: COMPARATOR
Intervention: Control condition (therapist time and environmental changes unrelated to cognitive deficits)
Number of subjects: 45
Study 12693434 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only
Number of subjects: 45
Study 10099034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (60 or 90 mg/d)
Number of subjects: 20
Study 10099034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10099034 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine and Placebo
Number of subjects: 20
Study 8574862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented maize-soybean porridge (F)
Number of subjects: 0
Study 8574862 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fermented maize-soybean porridge (NF)
Number of subjects: 0
Study 8574862 — intervention group
Group type: COMPARATOR
Intervention: Traditionally fermented maize-only porridge (P)
Number of subjects: 0
Study 1479277 — intervention group
Group type: EXPERIMENTAL
Intervention: Abscess tonsillectomy
Number of subjects: 53
Study 1479277 — intervention group
Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 53
Study 6232263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine maleate (100-200 mg/day)
Number of subjects: 50
Study 6232263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31421635 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) treatment (250 mg for 2 days, 500 mg for 2 days, 750 mg for 3 days, and 1000 mg for 5 weeks)
Number of subjects: 32
Study 31421635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29247343 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-maltodextrin mouth rinse (MR: 0.3 g/25 ml CAF: 1.6g/25 ml MALT)
Number of subjects: 10
Study 29247343 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-maltodextrin mouth rinse (MR)
Number of subjects: 10
Study 29247343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC: 25 ml artificial saliva)
Number of subjects: 10
Study 27965251 — intervention group
Group type: EXPERIMENTAL
Intervention: AKUD trial (app‐administered self‐care acupressure)
Number of subjects: 25
Study 27965251 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial compensation of €30
Number of subjects: 25
Study 25701338 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 supplementation
Number of subjects: 62
Study 25701338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 23886416 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.3 Gy × 10 fractions (target dose 43 Gy)
Number of subjects: 1566
Study 23886416 — intervention group
Group type: COMPARATOR
Intervention: 2.5 Gy × 20 fractions (target dose 50 Gy)
Number of subjects: 1566
Study 23886416 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon beams for parasternal fields
Number of subjects: 1566
Study 23886416 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.3 Gy regimen
Number of subjects: 1566
Study 20617051 — intervention group
Group type: EXPERIMENTAL
Intervention: PA intervention (one hour of moderate exercise three times a week for three months)
Number of subjects: 160
Study 20617051 — intervention group
Group type: COMPARATOR
Intervention: Control (normal exercise schedule provided by the school)
Number of subjects: 160
Study 20617051 — intervention group
Group type: EXPERIMENTAL
Intervention: PA intervention
Number of subjects: 160
Study 20617051 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study 17694310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 1000 mg/day with temozolomide for patients on EIAEDs
Number of subjects: 26
Study 17694310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/day with temozolomide for patients not on EIAEDs
Number of subjects: 26
Study 17694310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/day
Number of subjects: 26
Study 17694310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib and temozolomide combination
Number of subjects: 26
Study 17019957 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐intensive laser radiation (LILR) monotherapy
Number of subjects: 466
Study 17019957 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐intensive laser radiation (LILR) plus conventional drug therapy (CDT)
Number of subjects: 466
Study 17019957 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug therapy (CDT) only
Number of subjects: 466
Study 14620099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 180
Study 14620099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 10780761 — intervention group
Group type: EXPERIMENTAL
Intervention: zafirlukast 80 mg
Number of subjects: 19
Study 10780761 — intervention group
Group type: EXPERIMENTAL
Intervention: zafirlukast 20 mg
Number of subjects: 19
Study 10780761 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 9219407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial flashcard one‐to‐one education
Number of subjects: 201
Study 8205314 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 143
Study 8205314 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 143
Study 3305136 — intervention group
Group type: EXPERIMENTAL
Intervention: Manometric assessment
Number of subjects: 68
Study 3305136 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment (Control)
Number of subjects: 68
Study 29663430 — intervention group
Group type: EXPERIMENTAL
Intervention: B. Braun
Number of subjects: 12
Study 29663430 — intervention group
Group type: COMPARATOR
Intervention: FMC
Number of subjects: 12
Study 26918558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity WBV
Number of subjects: 84
Study 26918558 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity WBV
Number of subjects: 84
Study 26918558 — intervention group
Group type: COMPARATOR
Intervention: Control (no WBV)
Number of subjects: 84
Study 25291130 — intervention group
Group type: EXPERIMENTAL
Intervention: Active formulation containing 250 mg of tara gum and 1 billion viable cells of S. thermophilus ST10
Number of subjects: 25
Study 25291130 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 25
Study 22837118 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperedine (0.4 mg/Kg/IV)
Number of subjects: 90
Study 22837118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg/IV)
Number of subjects: 90
Study 22837118 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (Control)
Number of subjects: 90
Study 20600556 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (Consepsis)
Number of subjects: 80
Study 20600556 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 80
Study 18038601 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine in complex therapy
Number of subjects: 35
Study 18038601 — intervention group
Group type: COMPARATOR
Intervention: Mucaltin (control group)
Number of subjects: 35
Study 16129716 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium diet (1400 mg of calcium)
Number of subjects: 90
Study 16129716 — intervention group
Group type: COMPARATOR
Intervention: Moderate-calcium diet (800 mg of calcium)
Number of subjects: 90
Study 16129716 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium, increased fiber, low glycemic index diet
Number of subjects: 90
Study 16129716 — intervention group
Group type: COMPARATOR
Intervention: Control diet (standard diet with 800 mg of calcium)
Number of subjects: 90
Study 11872102 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL/hour
Number of subjects: 4
Study 11872102 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL/hour
Number of subjects: 4
Study 11872102 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mL/hour
Number of subjects: 4
Study 11872102 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL/hour
Number of subjects: 4
Study 11872102 — intervention group
Group type: EXPERIMENTAL
Intervention: All administration sets
Number of subjects: 4
Study 7852725 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid soap
Number of subjects: 10
Study 7852725 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate
Number of subjects: 10
Study 3416310 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-ethyl-10-deazaaminopterin (10-EDAM) i.v. at dosage levels ranging from 5 to 120 mg/m2
Number of subjects: 62
Study 3416310 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-EDAM i.v. weekly x 3 schedule (35 patients) or weekly schedule (27 patients)
Number of subjects: 62
Study 3416310 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-EDAM i.v. weekly at 80 mg/m2 or 100 mg/m2 weekly for 3 weeks
Number of subjects: 62
Study 3416310 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic studies at 5, 30, and 100 mg/m2 dosage levels
Number of subjects: 62
Study 31494486 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent valuation survey measuring willingness to pay for a 2% mortality risk reduction.
Number of subjects: 4000
Study 28404133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a plus nucleos(t)ide analogues
Number of subjects: 185
Study 28404133 — intervention group
Group type: COMPARATOR
Intervention: Nucleos(t)ide analogues alone
Number of subjects: 185
Study 25523060 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietetic consultations (8 sessions)
Number of subjects: 30
Study 25523060 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietetic consultations (8 sessions, attended all)
Number of subjects: 30
Study 24640432 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stabilized stannous fluoride (SnF2) dentifrice
Number of subjects: 96
Study 24640432 — intervention group
Group type: COMPARATOR
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 96
Study 21631949 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 327
Study 21631949 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-qPCR analysis
Number of subjects: 327
Study 21631949 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptome analysis
Number of subjects: 327
Study 19816648 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ibandronate 150 mg for 3 months
Number of subjects: 365
Study 19816648 — intervention group
Group type: COMPARATOR
Intervention: Weekly risedronate 35 mg for 12 weeks
Number of subjects: 365
Study 19816648 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ibandronate
Number of subjects: 365
Study 19816648 — intervention group
Group type: COMPARATOR
Intervention: Weekly risedronate
Number of subjects: 365
Study 19816648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 365
Study 16420193 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination protocol for identifying biomechanical and soft-tissue abnormalities
Number of subjects: 111
Study 15344186 — intervention group
Group type: COMPARATOR
Intervention: Experimental treatment
Number of subjects: 0
Study 11575038 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 17
Study 11575038 — intervention group
Group type: COMPARATOR
Intervention: Control (osteopathic structural examination only)
Number of subjects: 17
Study 11575038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received conventional therapy (antidepressant paroxetine plus weekly psychotherapy for 8 weeks)
Number of subjects: 17
Study 9148651 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 40
Study 9148651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9148651 — intervention group
Group type: EXPERIMENTAL
Intervention: Open phase (previous nonresponders receiving erythropoietin)
Number of subjects: 40
Study 9148651 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematologic response
Number of subjects: 40
Study 8120155 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 36
Study 8120155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3054783 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf lung surfactant extract in saline
Number of subjects: 34
Study 3054783 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 34
Study 5309529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(6.3) TCID(50)/ml
Number of subjects: 625
Study 5309529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(7.0) TCID(50)/ml
Number of subjects: 625
Study 5309529 — intervention group
Group type: COMPARATOR
Intervention: Multiple-pressure vaccination using undiluted vaccine
Number of subjects: 625
Study 5309529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(6.0) TCID(50)/ml
Number of subjects: 625
Study 5309529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal jet injection using diluted smallpox vaccine with a titre of 10(5.0) TCID(50)/ml
Number of subjects: 625
Study 5309529 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet vaccination
Number of subjects: 625
Study 31292007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary steroids (80 mg of methylprednisolone)
Number of subjects: 212
Study 31292007 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 212
Study 28287057 — intervention group
Group type: EXPERIMENTAL
Intervention: Story Method (mnemonic strategy with visualization and narrative structure)
Number of subjects: 61
Study 28287057 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery (mnemonic strategy of simple visualization of words)
Number of subjects: 61
Study 28287057 — intervention group
Group type: COMPARATOR
Intervention: Control condition (non-trained, equivalent exposure to training word lists)
Number of subjects: 61
Study 25269831 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon‐α‐2b
Number of subjects: 72
Study 25269831 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 72
Study 22584648 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ventricular reconstruction (SVR)
Number of subjects: 1000
Study 21811797 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol/APAP (37.5 mg/325 mg)
Number of subjects: 143
Study 21811797 — intervention group
Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 143
Study 21811797 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol/APAP
Number of subjects: 143
Study 21811797 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol/APAP and NSAID combination therapy
Number of subjects: 143